Outset Medical (NASDAQ:OM) Posts Quarterly Earnings Results, Misses Estimates By $0.34 EPS

Outset Medical (NASDAQ:OM) posted its earnings results on Monday. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.34), Zacks reports. Outset Medical had a negative net margin of 82.06% and a negative return on equity of 97.17%. Outset Medical updated its FY 2025 guidance to EPS.

Outset Medical Stock Up 0.1%

Shares of NASDAQ OM traded up $0.01 during mid-day trading on Monday, hitting $12.07. The company had a trading volume of 192,344 shares, compared to its average volume of 223,298. The company has a market capitalization of $214.48 million, a PE ratio of -0.59 and a beta of 2.14. The firm has a 50-day simple moving average of $13.98 and a two-hundred day simple moving average of $15.89. The company has a current ratio of 7.47, a quick ratio of 6.05 and a debt-to-equity ratio of 0.63. Outset Medical has a one year low of $5.85 and a one year high of $25.35.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. increased its position in shares of Outset Medical by 1,276.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 116,306 shares of the company’s stock worth $1,642,000 after purchasing an additional 107,854 shares during the last quarter. Massar Capital Management LP acquired a new stake in shares of Outset Medical in the 2nd quarter valued at approximately $384,000. BNP Paribas Financial Markets grew its stake in shares of Outset Medical by 7,013.8% in the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock valued at $40,000 after buying an additional 2,034 shares in the last quarter. Balyasny Asset Management L.P. acquired a new position in Outset Medical during the second quarter worth $2,750,000. Finally, Bank of America Corp DE raised its position in Outset Medical by 37,130.1% during the second quarter. Bank of America Corp DE now owns 135,890 shares of the company’s stock worth $2,610,000 after acquiring an additional 135,525 shares in the last quarter.

Wall Street Analyst Weigh In

OM has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Outset Medical in a report on Wednesday, October 8th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $22.00 price objective on shares of Outset Medical in a research report on Tuesday, August 19th. Finally, BTIG Research set a $37.00 price objective on Outset Medical and gave the stock a “buy” rating in a report on Monday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $24.67.

About Outset Medical

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.